<?xml version="1.0" encoding="UTF-8"?>
<p id="Par72">This strategy was implemented half a century ago in Argentina to decrease the mortality from Argentine hemorrhagic fever caused by the Jun√≠n virus from 30 to 3% [
 <xref ref-type="bibr" rid="CR65">65</xref>]. Experience from prior outbreaks with other coronaviruses, such as SARS-CoV, showed that such convalescent sera contain neutralizing antibodies to the relevant virus [
 <xref ref-type="bibr" rid="CR66">66</xref>]. This viewpoint argues human convalescent serum is an option for prevention and treatment of COVID-19 disease that could be rapidly available when there are sufficient numbers of people who have recovered and can donate immunoglobulin-containing serum [
 <xref ref-type="bibr" rid="CR67">67</xref>].
</p>
